Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain
| Autor: | Held, Mads Kjaergaard, Hansen, Olfred, Schytte, Tine, Hansen, Karin Holmskov, Bahij, Rana, Nielsen, Morten, Nielsen, Tine Bj��rn, Jeppesen, Stefan Starup |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Brain
Lung Neoplasms/diagnostic imaging Magnetic Resonance Imaging humanities respiratory tract diseases Small-cell lung cancer prophylactic cranial irradiation brain magnetic resonance imaging brain metastases limited-stage small-cell lung cancer extensive-stage small-cell lung cancer surgical procedures operative Brain Neoplasms/diagnostic imaging Humans Small Cell Lung Carcinoma/diagnostic imaging cardiovascular diseases Cranial Irradiation neoplasms Retrospective Studies |
| Zdroj: | Held, M K, Hansen, O, Schytte, T, Hansen, K H, Bahij, R, Nielsen, M, Nielsen, T B & Jeppesen, S S 2022, ' Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain ', Acta oncologica (Stockholm, Sweden), vol. 61, no. 2, pp. 185-192 . https://doi.org/10.1080/0284186X.2021.1974553 |
| DOI: | 10.1080/0284186X.2021.1974553 |
| Popis: | BACKGROUND: For decades many patients with small cell lung cancer (SCLC) have been offered prophylactic cranial irradiation (PCI) to prevent brain metastases (BM). However, the role of PCI is debated in the modern era of increased brain magnetic resonance imaging (MRI) availability. BM in SCLC patients may respond to chemotherapy, and if a negative MRI is used in the decision to use of PCI in the treatment strategy, the timing of brain MRI may be crucial when evaluating the effect of PCI. This retrospective study investigates the impact of PCI outcomes in patients with SCLC staged with brain MRI prior to chemotherapy.MATERIALS AND METHODS: This study included 245 patients diagnosed SCLC/mixed NSCLC-SCLC treated between 2012 and 2019. The population was analyzed separately for limited disease (LS-SCLC) and extensive disease (ES-SCLC). Patients were divided into groups based on baseline brain MRI prior to chemotherapy and PCI. The primary endpoint was time to symptomatic BM. Secondary endpoints were overall survival (OS), and progression-free survival (PFS).RESULTS: In patients with LS-SCLC staged with brain MRI the probability of developing symptomatic BM at one year was 4% vs. 22% (p CONCLUSION: This study found that PCI in LS-SCLC patients staged with brain MRI had lower incidence of symptomatic BM and improved survival outcomes suggesting PCI as standard of care. Similar benefit of PCI in patients with ES-SCLC was not found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|